Video - PROPHECY Trial: Circulating Tumor Cell as a Biomarker in mCRPC - Andrew Armstrong
Charles Ryan and Andrew Armstrong discuss the PROPHECY study, a PCF challenge award, co-funded by Movember. Seeing the future with predictive biomarkers was the foundational vision for this study. For men with castration-resistant prostate cancer undergoing a range of therapies, two AR-V7 tests were prospectively compared to see how well they predicted both progression-free survival and overall survival.
Andrew John Armstrong, MD, Medical Oncologist, Tenured Professor of Medicine, Surgery, Pharmacology and Cancer Biology and Associate Director of the Duke Cancer Institute’s Prostate and Urologic Cancer Center